연구성과로 돌아가기

2023 연구자 정보 (63 / 1135)

※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
Author Name 제1저자 여부 교신저자 여부 Address ResearcherID ORCID Paper Title WoS Edition 최상위 JCR(%) WoS Category Related Email
Lee, Yunjoo
(Lee, Y)
Northwestern Mem Hosp, Dept Internal Med, Chicago, IL 60611 USA

[JCR상위 1.7] Incidence, landscape and survival outcome of de novo malignancy after double lung transplantation.
[JCR상위 19.0] A Comprehensive Landscape of De Novo Malignancy After Double Lung Transplantation
[JCR상위 1.7] Machine learning models based on radiomics features to predict treatment response, biomarker status, and bone metastasis in patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs)
SCIE 1.7 ONCOLOGY
SURGERY;TRANSPLANTATION
ychae@nm.org;
Lim, Tien Huey
(Lim, TH)
Pusan Natl Univ, Coll Med, Dept Internal Med, Div Gastroenterol & Hepatol, Yangsan, South Korea

[JCR상위 1.7] Safety and efficacy of VIR-2218 with or without pegylated interferon alfa in virally-suppressed participants with chronic hepatitis B virus infection: post-treatment follow-up SCIE 1.7 GASTROENTEROLOGY & HEPATOLOGY mfyuen@hku.hk;
Lim, Woosung
(Lim, W)


[JCR상위 1.7] Prospective single-arm study of endocrine therapies with ovarian function suppression in premenopausal patients with node-positive early breast cancer with low genomic risk (INTERSTELLAR trial, KBCSG-25)
[JCR상위 1.7] Omission of breast surgery for predicted pCR patients with MRI and vacuum-assisted biopsy in breast cancer after neoadjuvant chemotherapy: A multicenter, single-arm, non-inferiority trial (OPTIMIST trial)
SCIE 1.7 ONCOLOGY
Macfarlane, Chelsea
(Macfarlane, C)
GSK, Waltham, MA USA

[JCR상위 1.7] Evidence of durable response to bepirovirsen in B-Clear responders: B-Sure first annual report SCIE 1.7 GASTROENTEROLOGY & HEPATOLOGY robert.c.elston@gsk.com;
Mak, Lung-Yi
(Mak, LY)
제1저자 Sch Clin Med, Dept Med, Hong Kong, Peoples R China
Univ Hong Kong, Queen Mary Hosp, State Key Lab Liver Res, Hong Kong, Peoples R China
ABB-1599-2020
Mak, Lung Yi (Loey)
0000-0002-2266-3935
Mak, Lung Yi
[JCR상위 1.7] A phase I/II study of ARO-HSD, an RNA interference therapeutic, for the treatment of non-alcoholic steatohepatitis SCIE 1.7 GASTROENTEROLOGY & HEPATOLOGY mfyuen@hku.hk;
Makowsky, Mallory
(Makowsky, M)


[JCR상위 1.7] Outcomes by occurrence of immune-mediated adverse events (imAEs) with tremelimumab (T) plus durvalumab (D) in the phase 3 HIMALAYA study in unresectable hepatocellular carcinoma (uHCC) SCIE 1.7 ONCOLOGY
Makris, Lukas
(Makris, L)


[JCR상위 1.7] Phase 2 study of bavituximab (bavi), a first-in-class antibody targeting phosphatidylserine (PS), plus pembrolizumab (P) in advanced gastric or gastroesophageal junction (GEJ) cancer SCIE 1.7 ONCOLOGY
Mameda, Naresh
(Mameda, N)
Koneru Lakshmaiah Educ Fdn, Dept Chem, Guntur 522302, Andhra Pradesh, India
Koneru Lakshmaiah Educ Fdn, Dept Engn Chem, Vaddeswaram 522302, Andhra Pradesh, India
AAV-2711-2020
Mameda, Dr. Naresh
0000-0002-0488-7521
Mameda, Naresh
[JCR상위 1.7] Bifunctional S-scheme hybrid heterojunction comprising CdS nanorods and BiOIO 3 nanosheets for efficient solar-induced antibiotic degradation and highly-selective CO 2 reduction
[JCR상위 44.1] Defective nano-silica loaded polymeric carbon nitride for visible light driven CO2 reduction and dye degradation
SCIE 1.7 MATERIALS SCIENCE, MULTIDISCIPLINARY;METALLURGY & METALLURGICAL ENGINEERING
CHEMISTRY, PHYSICAL
surendart@knu.ac.kr;
vidyasagar.devtade@gmail.com;ssumare1965@gmail.com;
Mao, Shenghua
(Mao, SH)
Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Div Gastroenterol & Hepatol, Dept Internal Med,Sch Med, Daegu, South Korea

[JCR상위 1.7] Safety and efficacy of VIR-2218 with or without pegylated interferon alfa in virally-suppressed participants with chronic hepatitis B virus infection: post-treatment follow-up SCIE 1.7 GASTROENTEROLOGY & HEPATOLOGY mfyuen@hku.hk;
Mccoy, Carrie L.
(Mccoy, CL)


[JCR상위 1.7] Outcomes by occurrence of immune-mediated adverse events (imAEs) with tremelimumab (T) plus durvalumab (D) in the phase 3 HIMALAYA study in unresectable hepatocellular carcinoma (uHCC) SCIE 1.7 ONCOLOGY
McEwen, Robert
(McEwen, R)


[JCR상위 1.7] Trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC) in patients (pts) with HER2-low, hormone receptor-positive (HR plus ) unresectable and/or metastatic breast cancer (mBC): Exploratory biomarker analysis of DESTINY-Breast04 SCIE 1.7 ONCOLOGY
Miklos, David Bernard
(Miklos, DB)
제1저자 교신저자 Stanford Univ, Sch Med, Stanford, CA 94305 USA
0000-0003-0717-4305
Miklos, David
[JCR상위 1.7] Ibrutinib for First-Line Treatment of Chronic Graft-Versus-Host Disease: Results From the Randomized Phase III iNTEGRATE Study SCIE 1.7 ONCOLOGY dmiklos@stanford.edu;
Mngqibisa, Rosie
(Mngqibisa, R)
Enhancing Care Fdn, Durban, South Africa JXM-3390-2024
Mngqibisa, Rosie

[JCR상위 1.7] Evidence of durable response to bepirovirsen in B-Clear responders: B-Sure first annual report SCIE 1.7 GASTROENTEROLOGY & HEPATOLOGY robert.c.elston@gsk.com;
Mockbee, Colleen M.
(Mockbee, CM)


[JCR상위 1.7] Phase 2 study of bavituximab (bavi), a first-in-class antibody targeting phosphatidylserine (PS), plus pembrolizumab (P) in advanced gastric or gastroesophageal junction (GEJ) cancer SCIE 1.7 ONCOLOGY
Mody, Kabir
(Mody, K)


[JCR상위 1.7] Outcomes by occurrence of immune-mediated adverse events (imAEs) with tremelimumab (T) plus durvalumab (D) in the phase 3 HIMALAYA study in unresectable hepatocellular carcinoma (uHCC) SCIE 1.7 ONCOLOGY
페이지 이동: